US genetic medicines developer Estuary Biotherapeutics today announced its launch with $103 million in total committed ...

US drugmaker Ironwood Pharmaceuticals, which is focused on gastrointestinal and rare diseases, has announced a leadership ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended four novel medicines and two biosimilars ...

Singapore based clinical-stage biotech Adlai Nortye Group has entered into clinical trial collaboration and supply agreements ...

US biotech company Iambic Therapeutics (Nasdaq: IAM) has priced a $150 million initial public offering (IPO), securing ...

Fractyl Health today announced top-line six-month results from the Pivotal Cohort of its ongoing REMAIN-1 study (Pivotal ...

Belgian biotech Lakefront Biotherapeutics (Euronext: LKFT), formerly Galapagos, has sold its preclinical cell therapy ...

Cambridge, UK based Microbiotica, a clinical-stage biopharma company developing a pipeline of orally-dosed, precision ...

US healthcare investment firm OrbiMed has raised $3 billion in commitments for two funds targeting companies across the USA, ...

Shares in Swedish biotech Modus Therapeutics fell by half in Stockholm trading on Thursday after the company paused ...

The US regulator, the Food and Drug Administration (FDA), has launched an initiative to reshape rare disease drug development ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is introducing a series of new measures to strengthen how ...